INTRODUCTION
• Osteosarcoma is the most common primary malignant bone cancer in children. 1 • It frequently develops in fast growing bones such as the distal femur or proximal tibia. 1 • The median age of patients is 20 years old. 1 • 10%-20% of cases are metastatic at diagnosis, with the lungs being the most common metastatic site. 2 • There is a lack of information about the cost of metastatic unresectable osteosarcoma.
METHODS
• 
RESULTS
*The chemotherapy regimens were the major cost components associated with this disease.
• Cisplatin, ifosfamide, and epirubicin cost $38,936 per patient. 3 • Doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide cost $38,404 per patient. 4 • Doxorubicin and cisplatin cost $17,549 per patient. [5] [6] [7] • Doxorubicin, cisplatin, and high-dose methotrexate cost $103,051 per patient. [8] [9] CONCLUSIONS • A guideline-based disease model can assist health plans to better understand and anticipate the resources required and the expected cost of diagnosis, treatment, and surveillance of unresectable metastatic osteosarcoma patients. Further research is needed to determine the real-world cost and the cost effectiveness of chemotherapy regimens.
